EXACT Therapeutics - webcast presentation

Oslo, Norway, 4 June 2026. Reference is made to the stock exchange announcement published 1 June 2026 by EXACT Therapeutics AS (the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, announcing that Company will host a webcast in connection with the proposed delisting of the Company's ordinary shares from Euronext Growth, Oslo on Thursday, 4 June 9.30 CEST.

The presentation will be held by the Chair of the Board, Anders Wold; the Company’s CEO, Per Walday; and CFO, John M. Edminson.

Attached is the presentation for the webcast.

The presentation will also be available on the Company homepage: www.exact-tx.com

About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com

For further information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com